Results 21 to 30 of about 92,728 (309)

Chronic lymphocytic leukemia

Annals of Oncology, 2010
The management of chronic lymphocytic leukemia (CLL) is currently undergoing a profound change. First, several new drugs have been approved (fludarabine, bendamustine and two monoclonal antibodies, alemtuzumab and rituximab). In addition, novel monoclonal antibodies targeting CD20, CD23, CD37 or CD40, as well as drugs designed to interfere with central
Michael, Hallek, Natali, Pflug
openaire   +2 more sources

Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia

Haematologica, 2018
Chronic lymphocytic leukemia is a disease with up-regulated expression of the transmembrane tyrosine-protein kinase ROR1, a member of the Wnt/planar cell polarity pathway. In this study, we identified COBLL1 as a novel interaction partner of ROR1. COBLL1
Hana Plešingerová, Pavlína Janovská, Archana Mishra, Lucie Smyčková, Lucie Poppová, Antonín Libra, Karla Plevová, Petra Ovesná, Lenka Radová, Michael Doubek, Šárka Pavlová, Šárka Pospíšilová, Vítězslav Bryja   +12 more
doaj   +1 more source

Cyclosporine A therapy of chronic lymphoblastic leukemia‐related pancytopenia: A case report

Clinical Case Reports, 2022
To explore the clinical characteristics, diagnosis, and treatment of chronic lymphocytic leukemia with secondary pancytopenia. Here, a case of pancytopenia secondary to chronic lymphocytic leukemia is reported.
Mengying Wang, Ruoyu Meng, Yan Gao, Junxia Huang, Tianlan Li, Chunxia Mao, Shanshan Liu, Yujie Xu, Han Xu, Xianqi Feng   +9 more
doaj   +1 more source

Impact of leukemia subtype and demographics on patient quality of life in 76 countries: a cross-sectional study

Frontiers in Hematology
BackgroundDisease-specific factors associated with decreased quality of life (QoL) in patients with leukemia have not been studied in a large-scale, global, observational study.MethodsThis cross-sectional study used the validated Hematological Malignancy
Sam Salek, Samantha Nier, Zack Pemberton-Whiteley, Tatyana Ionova, Giuseppe Ianni, Giovanni Tripepi, Nick York, Nicole Schroeter, Kathryn Huntley, Michael Rynne, Denis Costello, Lidija Pecova, Esther Natalie Oliva   +12 more
doaj   +1 more source

Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6

, 2013
The authors acknowledge TENOVUS Tayside for funding the studyTenovin-6 (Tnv-6) is a bioactive small molecule with anti-neoplastic activity. Inhibition of the Sirtuin class of protein deacetylases with activation of p53 function is associated with the pro-
Coates, Philip J., Groves, M.J., Prescott, A.R., Nicolaou, A., Murray, Karen, Ganley, Ian G.; id_orcid, Lain, S., Tauro, S., Haydock, S., Appleyard, V., Ganley, I.G., James, John, Nicolaou, Anna; id_orcid, Cunningham, Joan, Cunningham, J., Tauro, Sudhir, Murray, K., Prescott, Alan R., Drbal, Abed Alnaser A.A., Coates, P.J., James, J., MacCallum, S., Lain, Sonia, Drbal, A.A., MacCallum, Stephanie F., Drbal, Abed A., Haydock, Sally, Westwood, N.J., Prescott, Alan R.; id_orcid, Ganley, Ian G., Groves, Michael J., Nicolaou, Anna, Westwood, Nicholas J., Appleyard, Virginia   +33 more
core   +1 more source

Leukemia cutis in a patient with chronic lymphocytic leukemia presenting as bilateral helical nodules

SAGE Open Medical Case Reports, 2016
Chronic lymphocytic leukemia, the most common adult leukemia worldwide, is considered an indolent but incurable non-Hodgkin lymphoma. Leukemia cutis is an uncommon manifestation of chronic lymphocytic leukemia.
Ali Raufi, Mohamed Alsharedi, Yousef Khelfa, Doreen C Griswold, Yehuda Lebowicz   +4 more
doaj   +1 more source

Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia

Haematologica, 2016
Abroad array of conditions can lead to neurological symptoms in chronic lymphocytic leukemia patients and distinguishing between clinically significant involvement of the central nervous system by chronic lymphocytic leukemia and symptoms due to other ...
Paolo Strati, Joon H. Uhm, Timothy J. Kaufmann, Chadi Nabhan, Sameer A. Parikh, Curtis A. Hanson, Kari G. Chaffee, Timothy G. Call, Tait D. Shanafelt   +8 more
doaj   +1 more source

Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin

Haematologica, 2018
Chronic lymphocytic leukemia is a malignancy of mature B cells that strongly depend on microenvironmental factors, and their deprivation has been identified as a promising treatment approach for this incurable disease.
Claudia Dürr, Bola S. Hanna, Angela Schulz, Fabienne Lucas, Manuela Zucknick, Axel Benner, Andrew Clear, Sibylle Ohl, Selcen Öztürk, Thorsten Zenz, Stephan Stilgenbauer, Min Li-Weber, Peter H. Krammer, John G. Gribben, Peter Lichter, Martina Seiffert   +15 more
doaj   +1 more source

Targeting S100A9-mediated inflammation: a novel therapeutic approach for CLL

Blood Advances
: Chronic lymphocytic leukemia (CLL) presents challenges in treatment despite advancements in targeted therapies, often facing resistance or relapse. Chronic inflammation plays a significant role in CLL biology, with heightened inflammatory responses and
Angimar Uriepero-Palma, Maria Elena Márquez, Eugenia Payque, Melanie Mediavilla-Varela, Wael Gamal, Kamira Maharaj, John Powers, Julio Chavez, Erika Eksioglu, Sandra Sernbo, Florencia Palacios, Juliana Querol-Rivas, Claudia Ortega, Rita Uria, Gimena Dos Santos, Carolina Oliver, Ana Inés Landoni, Eva Sahakian, Pablo Oppezzo, Javier Pinilla-Ibarz   +19 more
doaj   +1 more source

[Chronic lymphocytic leukemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2014
Currently, several novel drugs are available for chronic lymphocytic leukemia (CLL) in Western countries. Of these drugs, those that inhibit the B-cell receptor (BCR) signaling pathway are the most promising. Ibrutinib inhibits BTK in the BCR pathway and can be administered orally. The results of several clinical trials suggest that ibrutinib is highly
openaire   +3 more sources